Biochemistry of Neurodegeneration (IV-S19)

Chairs: Yves Agid
  Michael Ugrumov

July 7, 2013

17.00 - 17.40

Bart De Strooper   VIB Center for the Biology of Disease, Leuven, Belgium

Aberrant proteolytic processing in Alzheimer’s Disease: pitfalls and hope for a therapy

17.40 - 18.05

Anthony Turner   Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, UK

The amyloid precursor protein: biochemical enigma in brain development, function and disease

18.05 - 18.30

Sergei Kozin   Engelhardt Institute of Molecular Biology RAS, Moscow, Russia

Molecular determinants of Alzheimer’s disease

18.30 - 18.45

Aleksey Alekseev   Institute for Systems Biology St Petersburg, Russia

Kinetic model of Aβ distribution and aggregation in human

18.45 – 19.00

Maria Ryazantseva   Institute of Cytology, Russian Academy of Sciences, St Petersburg, Russia

Familial Alzheimer’s disease PS1 gene mutants affect activity of calcium channels differently

19.00 – 19.15

Montserrat Arrasate   Center for Applied Medical Research (CIMA), School of Medicine, University of Navarra, Pamplona, Spain

A longitudinal microscope-based methodology to assess the effect of alpha-synuclein pathological mutations on stability and survival in primary cortical neurons

19.15 – 19.30

Agnese De Mario   Department of Experimental Biomedical Sciences, University of Padua, Padua, Italy

The role of the prion protein in neurodegenerative disorders

19.30 – 19.45

Francesca Amati   Department of Medical Basic Sciences, Neurosciences and Sense Organs University of Bari “Aldo Moro”, Bari, Italy

S100A4 calcium binding protein is differently expressed in patients with early-onset Parkinson’s disease associated with PINK1 W437X and PARK2 gene mutations